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ABSTRACT 
Objectives: Endometrial endometrioid carcinoma (EEC) is the most encountered subtype of 
endometrial cancer (EC). Our study aimed to investigate the factors affecting recurrence in 
patients with stage 1A and 1B EEC.  
Material and methods: Our study included 284 patients diagnosed with the International 
Federation of Gynecology and Obstetrics stage 1A/1B EEC in our center from 2010 to 2018. 
 
 
The clinicopathological characteristics of the patients were obtained retrospectively from their 
electronic files.  
Results: The median age of the patients was 60 years (range 31–89). The median follow-up 
time of the patients was 63.6 months (range 3.3–185.6). Twenty-two (7.74%) patients 
relapsed during follow-up. Among the relapsed patients, 59.1% were at stage 1A ECC, and 
40.9% were at stage 1B. In our study, the one-, three-, and five-year recurrence-free survival 
(RFS) rates were 98.9%, 95.4%, and 92.9%, respectively. In the multivariate analysis, grade 
and tumor size were found to be independent parameters of RFS in all stage 1 EEC patients. 
Furthermore, the Ki-67 index was found to affect RFS in stage 1A EEC patients, and tumor 
grade affected RFS in stage 1B EEC patients. In the time-dependent receiver operating 
characteristic curve analysis, the statistically significant cut-off values were determined for 
tumor size and Ki-67 index in stage 1 EEC patients.  
Conclusions: Stage 1-EEC patients in the higher risk group in terms of tumor size, Ki-67, and 
grade should be closely monitored for recurrence. Defining the prognostic factors for 
recurrence in stage 1 EEC patients may lead to changes in follow-up algorithms. 
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While the most common gynecological malignancy in developed countries is 
endometrial cancer (EC), it ranks second after cervical cancer in developing countries [1]. 
Approximately 75–90% of patients with EC present with abnormal uterine bleeding, and the 
most important risk factors are obesity, type 2 diabetes mellitus (DM), high fatty diet, early 
menarche, nulliparity, late menopause, Lynch syndrome, age > 55 years and chronic 
tamoxifen use [2–6]. 
In the traditional classification, EC is divided into two types: estrogen-driven type 1, 
which includes grades 1–2 endometrial endometrioid carcinomas (EEC), and non-estrogen-
driven type 2, which consists of grade 3 EEC and non-endometrioid carcinomas [7]. EEC is 
the most common subtype, comprising 75%–80% of EC [8].  
The stage of EC can be determined using the International Federation of Gynecology 
and Obstetrics (FIGO) system. In the FIGO staging system, less than half of myometrial 
invasion is defined as stage 1A, and invasion equal to or more than half of the myometrium is 
defined as stage 1B EEC [9]. However, FIGO staging alone is inadequate for treatment 
planning in patients with stage 1 EEC. In the National Comprehensive Cancer Network 
(NCCN) guidelines, besides myometrial invasion, risk factors such as pathological grade, ≥ 
60 years, and lymphovascular invasion are recommended for making therapy decisions. 
According to risk factors, observation or brachytherapy is recommended after surgery in stage 
1A disease [10]. The NCCN uterine cancer guideline recommends brachytherapy ± external 
beam radiation therapy or radiation therapy ± chemotherapy after surgery in stage 1B disease 
[10]. In stage 1A and 1B EEC disease, a few patients relapse despite current treatment 
options.  
Our study aimed to investigate the factors affecting recurrence in patients with stage 
1A and 1B EEC and identify the clinicopathological features of patients who should be 






MATERIAL AND METHODS 
 
Study population and data collection 
Our study included 284 patients diagnosed with stage 1A/1B endometrial 
endometrioid carcinoma according to the FIGO 2009 staging system between 2010 and 2018 
in the Departments of Medical and Gynecological Oncology, Bursa Uludag University. The 
patients who could not be staged, who had a second history of malignancy, and who were 
under the age of 18 were excluded. 
As study variables, the demographic characteristics (age, body mass index, presence of 
DM and parity), histopathological features (tumor size, lower uterine segment involvement, 
lymphovascular space invasion, and accompanying non-tumor lesion), total abdominal 
hysterectomy (TAH) and bilateral salpingo-oophorectomy  (BSO) and TAH and BSO plus 
bilateral pelvic paraaortic lymph node dissection (BPPLND) as surgical types, external 
radiotherapy, brachytherapy and chemoradiotherapy as applied treatments as well as 
oncological results (follow-up time, any recurrence development and recurrence-free survival) 
were obtained retrospectively from the patients' electronic files. In addition to all these 
variables, estrogen receptor (ER), progesterone receptor (PR), Ki-67 level, tumor grade and 
myometrial invasion were obtained from the histopathological examination.  
Treatment features 
Surgical treatment of endometrial cancer in our institution is a total hysterectomy and 
bilateral salpingo-oophorectomy. Intraoperative frozen section analysis was routinely 
performed in all cases. Pelvic and paraaortic lymphadenectomy is also performed for women 
whose frozen section analysis reveals a tumour type other than EEC, grade 3 histology, 
cervical invasion, myometrial invasion greater than 50% depth, and tumour size greater than 2 
cm. 
Brachytherapy was applied to the patients with stage 1A/grade 1–2 EEC, in the 
presence of high-risk factors  (lymphovascular space invasion and age ≥ 60). Brachytherapy 
was applied to all patients to patients with stage 1A/grade3 and stage 1B. The treatment dose 
was given to the vaginal 1/3 apex area, 5 mm deep from the vaginal surface with a high dose 
rate brachytherapy device using the Ir-192 source. The doses applied to the vaginal mucosa, 
 
 
rectum, and bladder were calculated according to International Commission on Radiation 
Units and Measurements. A total dose of 18–24 gray (Gy) was planned with a fraction dose of 
6–7 Gy. External radiotherapy was applied to stage 1B/grade 3 cases. The total dose of 45 Gy 
(1.8 Gy per fraction) was delivered to the primary tumor site and pelvic lymph nodes. 
Histological examination  
Hematoxylin-Eosin and immunohistochemical staining of specimens (Ki-67, ER and 
PR) were re-evaluated, and histopathological features (grade, myometrial invasion) were 
recorded. The slides of the cases were evaluated using a light microscope (model BX51TF, 
Olympus, Tokyo, Japan). Histological grading was performed using the International 
Federation of Gynecology and Obstetrics (FIGO) grading system. Myometrial invasion depth 
was evaluated in two categories of being less than half (less than 50%) or more than half 
(50% or more ) in the slide with the deepest tumor penetration. The ER assay clone used was 
SP1, the PR assay clone used was 1E2, and the Ki-67 assay clone used was 30–9. Only 
nuclear staining was considered as positive immunostaining for ER, PR, and Ki-67, and 
staining was scored according to the percentage of nuclear staining. Staining of  > 1% of 
tumor cell nuclei is considered positive for ER and PR staining. For Ki-67, at least 1000 cells 
were counted at x400 magnification from the hot-spot areas in each sample. 
Outcomes 
Recurrence-free survival (RFS) was defined as the time between the date of surgical 
staging and the date of histologically or radiologically confirmed recurrence. Overall survival 
(OS) was determined from the time of diagnosis until death from any cause.  
Ethics 
Our study was conducted in accordance with the 1964 Helsinki declaration. The 
clinical research ethics committee of the Bursa Uludag University Faculty of Medicine 
approved the study (Approval number: 2020-6/33). As this study is based on retrospective 
analysis of encrypted data, informed consent was not needed. 
Statistical analysis 
The continuous variables were expressed by the mean and median values, and the 
categorical variables were expressed by frequency and the corresponding percentage values. 
Survival analysis was calculated using the Kaplan-Meier method. The factors were examined 
 
 
by Cox Regression Analysis. The enter model was used with the parameters having a p-value 
below 0.20 to determine the independent factors. The data were statistically processed using 
IBM SPSS version 22 software. In all statistical analyses, p < 0.05 was accepted as 
statistically significant for the results. A time-dependent receiver operating characteristic 
(ROC) curve analysis was performed with R software version 3.4.2 and the survival ROC 
package version 1.0.3. The nearest neighbor estimator with a span of  λ = 0.05 was used. The 
cut-off point that achieves this maximum Youden-J index was accepted as the optimal cut-off 




The clinicopathological features of and treatment options for stage 1 EEC patients are 
presented in Table 1. The median age of patients was 60 years (range 31–89). The median 
body mass index (BMI) of the patients was 33.6 (range 20.4–63.7) kg/m2. Among the 
patients, 118 (41.6%) had a history of DM, 88.7% were multiparous, 54.6% underwent TAH 
with BSO and BPPLND, 77.8% were at stage 1A, and 22.2% were at stage 1B. The median 
tumor size was 3.2 cm (range 0.3–10.0). 42 (14.8%) patients had no myometrial invasion, 179 
(63.0%) had less than 50% myometrial invasion, and 63 (22.2%) had 50% or more 
myometrial invasion. 
Most of the patients were in grade 1 (48.9%). The median Ki-67 index was 20 (range 
1.0–90.0). Among the patients, 61 (21.5%) had lower uterine segment involvement, 16 (5.6%) 
had lymphovascular invasion, and 65 (22.9%) had adenomyosis. The number of patients with 
a positive estrogen receptor (ER) and a positive progesterone receptor (PR) was 243 and 240, 
respectively. After surgery, 159 (56.0%) patients were treated with radiotherapy, five patients 
(1.7%) with chemoradiotherapy. Among the patients, 42.3% were followed up without 
treatment.  
Oncological outcomes 
The median follow-up time of the patients was 63.6 months (range 3.3–185.6). Twenty-two 
(7.74%) patients relapsed during follow-up. Among the relapsed patients, 59.1% were at stage 
1A ECC, and 40.9% were at stage 1B. The median time between diagnosis and tumor 
recurrence was 33.4 (range 3.9–100) months. Tumor recurrence occurred in the vagina in nine 
 
 
patients, in the lung in five patients, in the peritoneum in four patients, in the bladder in one 
patient, in the colon in one patient, in the intra-abdominal lymph node in one patient, and in 
the bone in one patient. 
In our study, the one-, three-, and five-year RFS rates were 98.9%, 95.4%, and 92.9%, 
respectively. The OS  rates for one, three, and five years were 99.3%, 95.4%, and 93.3%, 
respectively.  
The factors affecting recurrent free survival for all FIGO stage 1 EEC patients in the 
study 
The factors affecting RFS in FIGO stage 1 EEC patients were evaluated after 
univariate analysis, and grade, myometrial invasion, tumor size, ER, PR, and Ki-67 index 
were included in the multivariate analysis. In the multivariate analysis, grade and tumor size 
had a statistically significant effect on disease recurrence (p = 0.034, p = 0.011, respectively) 
(Tab. 2).  
The time-dependent ROC curve analysis was performed to obtain a cut-off value for 
tumor size, which had an effect on relapse in stage 1 ECC patients. In the time-dependent 
ROC curve analysis for tumor size, the AUC was found to be significant for the time intervals 
of 26.4–32.6 and 74.2–100 (months). The cut-off values corresponding to the maximum 
Youden-J index were 3 cm and 2.2 cm, respectively. This finding means that a tumor size 
greater than 3.0 cm predicts recurrence after 26.4 months and that a tumor size greater than 
2.2 cm predicts recurrence after 74.2 months significantly. No significant AUC was found for 
the other time points (Tab. 3). The time-dependent ROC curves of the tumor size for the 
26.4–32.6 time interval and for the 74.2–100 time interval are presented in Figure 1.  
The factors affecting recurrent free survival for FIGO stage 1A EEC patients 
Grade, Ki-67 index, ER, adjuvant therapy and lower uterine segment involvement 
were included in the multivariate Cox regression analysis in which stage 1A EEC patients 
were evaluated. The Ki-67 index had a statistically significant effect on RFS (p = 0.019) 
(Table 4). A time-dependent ROC curve analysis was performed to obtain a cut-off value for 
the Ki-67 index. Stage 1A patients were analyzed for the Ki-67 index, and no significant 
AUC value was found in the time-dependent ROC curve analysis. Also, time-dependent ROC 
curve analysis was performed to evaluate the Ki-67 index in all stage 1 EEC patients. For Ki-
67, the AUC was found to be significant for the time interval of 64.2–74.1 and 74.1–185.6 
 
 
(months). The cut-off values were 30% and 20%, respectively. This means that Ki-67 values 
greater than 30% predicted recurrence after 64.2 months and that Ki-67 values greater than 
20% predicted recurrence after 74.1 months significantly. No significant AUC was found for 
the other time points (Tab. 5). 
The factors affecting recurrent free survival for FIGO stage 1B EEC patients  
After the univariate analysis, age, BMI, grade, tumor size, and PR status of stage 1B 
ECC patients were included in the multivariate analysis, and the grade was found to have a 
statistically significant effect on RFS for stage 1B patients (p = 0.031) (Tab. 6). The effect of 
grade on RFS is presented in Figure 2. 
 
DISCUSSION 
In this study, we found tumor size and grade as prognostic factors for recurrence with 
multivariate analysis in stage 1 EEC patients, while we found that Ki-67 index in stage 1A 
EEC patients and tumor grade in stage 1B EEC patients were prognostic factors affecting 
recurrence.  
In many studies, EC patients were evaluated according to FIGO staging as stages 1–4 
[11–14] or stages 1–2 [15–17]. Although these studies provide general information about 
relapse-related factors and survival in EC patients, there are a limited number of studies about 
stage 1 EEC disease. To our knowledge, except for the study of Han et al. [18], there is no 
large-scale research investigating the recurrence factors in stage 1A and 1B EEC disease.  
Many studies have confirmed the prognostic value of grade in EC patients [11, 16, 
18]. Han et al. [18] study showed that grade was a statistically significant factor for recurrence 
in all patients with stage 1 EEC. However, multivariate analysis revealed that tumor grade 
was an independent factor for recurrence in patients with stage 1B disease, and myometrial 
invasion was an independent factor in patients with stage 1A disease. Likewise, in our study, 
we found that tumor grade is an independent prognostic factor on recurrence in stage 1 EEC 
patients and stage 1B EEC patients, not for stage 1A. Therefore, our study is one of the 
studies showing that these features are prognostic factors. 
Although there are studies in which tumor size is not one of the factors affecting 
survival in patients with EEC [16, 18, 19],  Schink JC. et al. [20] evaluated stage 1 ECC 
 
 
patients and reported that tumor size was a prognostic factor for survival, as in our study. In 
this study, the cut-off value was 2 cm. In the time-dependent ROC curve analysis for tumor 
size, the risk of recurrence increased after 26.4 months in patients with a tumor size greater 
than 3 cm and after 74.2 months in patients with a tumor size greater than 2.2 cm. 
Except for resting cells (G0), Ki-67 protein is expressed at all active cell cycle stages 
(G1, S, G2, M) [21]. It is used as a marker of cellular proliferation; its prognostic and 
predictive value was shown in several cancer types, including endometrial cancer [22, 23]. 
Kitson et al. [24] investigated prognostic factors, including Ki-67 in stages 1–4 EC patients. 
Ki-67 was associated with worsening of cancer-specific survival in the univariate analysis. 
However, this significance was not detected in the multivariate analysis.  Yu et al. [25], 
examined stages 1–4 EC patient group and found that Ki-67 was associated with stage, 
differentiation, depth of myometrial invasion, and lymph node status. The studies 
investigating the importance of Ki-67 consisted mainly of all EC subtypes and stages 1–4 
patient groups. To the best of our knowledge, our research is the first to show the effect of the 
Ki-67 index on recurrence in stage 1A disease in the multivariate analysis. In the study, no 
statistically significant cut-off value was determined in the time-dependent ROC analysis for 
Ki-67 in stage 1A EEC patients. However, in all stage 1 ECC patients, Ki-67 values greater 
than 30% predicted recurrence after 64.2 months, and Ki-67 values greater than 20% 
predicted recurrence after 74.1 months significantly.  
The depth of myometrial invasion has been used for staging EEC [9]. In Han et al.'s 
[18] study, myometrial invasion in stage 1A EEC disease was found to be a prognostic factor 
in recurrence. Our study included similar patient groups, but the depth of myometrial invasion 
was not detected as a prognostic factor for recurrence in stage 1A EEC patients. Akar et al. 
[16] found that myometrial invasion was not associated with RFS and disease-specific 
survival in patients with stages 1–2 EEC. This finding should be compared with those of 
studies involving larger groups of stage 1A patients. In our study and Han et al.'s [18] study, 
age, lymphovascular involvement, lower uterine segment involvement, lymph node 
dissection, and adjuvant therapy were not prognostic factors recurrence in stage 1 EEC 
patients. In addition to Han et al., we also studied factors such as BMI, DM, parity, ER and 
PR status, and presence of adenomyosis. These factors were not found to be prognostic 





Our study's main limitations are its retrospective design and the limited number of 
relapsed patients. Moreover, there were not enough death events to analyze OS or cancer-
specific survival. 
CONCLUSIONS  
Tumor grade and size were found to be the independent parameters for RFS in all 
stage 1 EEC patients. The Ki-67 index affected RFS in stage 1A EEC patients, and tumor 
grade affected RFS in stage 1B EEC patients. In the time-dependent ROC curve analysis, 
statistically significant cut-off values were determined for tumor size and the Ki-67 index in 
stage 1 EEC patients. Stage 1-EEC patients in a higher risk group for tumor size, Ki-67 index, 
and grade, should be closely monitored for recurrence. Defining the prognostic factors for 
recurrence in stage 1 EEC patients may lead to changes in follow-up algorithms. 
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Table 1. Clinicopathological features and treatment options of stage 1 EEC patients  
Characteristic N (%) 
Age (Median) (Range, years) 60.0 (31.0–89.0) 
BMI (Median) (Range, kg/m2) 33.6 (20.4–63.7) 












Surgery TAH with BSO 











Tumor size (Median) (Range, cm) 3.2 (0.3–10.0) 


















Ki-67 (median) (range, %) 20 (1.0–90.0) 















































EEC — endometrial endometrioid carcinomas; ECOG — Eastern Cooperative Oncology 
Group; BMI — body mass index; TAH — total abdominal hysterectomy; BSO — bilateral 
salpingo-oophorectomy; BPPLND — bilateral pelvic paraaortic lymph node dissection 
 
 
Table 2. Univariate and multivariate cox regression analysis of the predictors for all patients recurrence 
Factor  Univariate Analysis Multivariate Analysis 
Grade 3-4 
 HR % 95 CI p HR % 95 CI p 
Age Years 1.001 0.959–1.044 0.962    
BMI kg/m2 0.997 0.943–1.054 0.918    
Diabetes mellitus Absent (RC) vs Present 1.037 0.455–2.363 0.931    
Parity Nullipar (RC) vs Multipar 1.017 0.300–3.446 0.978    
Grade  3.914 2.068–7.408 < 0.001 2.5
08 
1.066–5.901 0.035 
Myometrial invasion < 50% (RC) vs ≥ 50% 1.899 0.796–4.534 0.148 0.9
85 
0.311–3.116 0.980 
Tumor size cm 1.303 1.035–1.642 0.025 1.3
86 
1.058–1.818 0.018 
Lymphovascular space invasion Absent (RC) vs Present 1.732 0.639–4.698 0.281    
Lymph node dissection Absent (RC) vs Present 1.153 0.497–2.675 0.741    
Adenomyosis Absent (RC) vs Present 1.294 0.497–2.675 0.741    
Ki-67 % 1.027 1.007–1.048 0.009 1.0
18 
0.992–1.044 0.171 
Estrogen receptor status Negative (RC) vs Positive 3.395 0.974–11.834 0.055 6.8
18 
0.774–60.077 0.084 
Progesterone receptor status Negative (RC) vs Positive 3.360 0.776–14.558 0.105 0.2
82 
0.015–5.303 0.398 
Lower uterine segment involvement Absent (RC) vs Present 1.392 0.565–3.428 0.472    
Adjuvant therapy Absent (RC) vs Present 3.585 0.478–26.876 0.214    
HR — hazard ratio; CI — confidential interval; BMI — body mass index; RC — reference category 




Table 3. Time-dependent ROC curve analysis results and accuracy summaries for tumor size 
Time Interval AUC p-value cut-off Youden J Sensitivity Specificity LR+ LR– 
[3.3–4.3) 0.005 1.000 – – – – – – 
[4.3–6.5) 0.214 0.999 – – – – – – 
[6.5–9.2) 0.245 0.893 – – – – – – 
[9.2–13.4 0.559 0.401 – – – – – – 
[13.4–20) 0.539 1.000 – – – – – – 
[20–21.3) 0.512 0.464 – – – – – – 
[21.3–22.1) 0.558 0.322 – – – – – – 
[22.1–25.8) 0.578 0.220 – – – – – – 
[25.8–26) 0.592 0.137 – – – – – – 
[26–26.4) 0.629 0.061 – – – – – – 
[26.4–32.6) 0.635 0.039 3 0.250 0.745 0.505 1.505 0.505 
[32.6–34.2) 0.562 0.226 – – – – – – 
[34.2–36.3) 0.531 0.350 – – – – – – 
[36.3–38) 0.519 0.399 – – – – – – 
[38–40) 0.543 0.271 – – – – – – 
[40–46.7) 0.539 0.272 – – – – – – 
[46.7–51) 0.565 0.272 – – – – – – 
[51–60.1) 0.544 0.245 – – – – – – 
[60.1–64.2) 0.583 0.245 – – – – – – 
[64.2–74.1) 0.593 0.068 – – – – – – 
[74.1–74.2) 0.620 0.068 – – – – – – 
[74.2–100) 0.611 0.034 2.2 0.159 0.872 0.286 1.222 0.446 
[100–185.6] 0.582 0.096 – – – – – – 
AUC — area under the ROC curve; LR+ — positive likelihood ratio; LR — negative likelihood ratio 
 
 
Table 4. Univariate and multivariate cox regression analysis of the predictors for stage 1A patients recurrence 
Factor  Univariate Analysis Multivariate Analysis 
Grade 3-4 
 HR %95 CI p HR %95 CI p 
Age Years 1.039 0.974–1.109 0.247    
BMI kg/m2 0.976 0.905–1.052 0.519    
Diabetes mellitus Absent (RC) vs Present 0.734 0.244–2.206 0.581    
Parity Nullipar (RC) vs Multipar 2.030 0.263–15.676 0.497    
Grade   2.723 1.127–6.580  0.026 1.096 0.345–3.481 0.87
77 
Myometrial invasion Absent (RC) vs Present 0.185 0.008–4.085 0.286    
Tumor size cm 1.121 0.793–1.584 0.519    
Lymphovascular space invasion Absent (RC) vs Present 1.706 0.377–7.729 0.488    
Lymph node dissection Absent (RC) vs Present 1.741 0.567–5.340 0.332    
Adenomiyozis Absent (RC) vs Present 1.959 0.640–5.994 0.239    
Ki-67 % 1.030 1.001–1.060 0.045 1.036 1.006–1.067  0.01
9 
Estrogen receptor status Negative (RC) vs Positive 4.451 0.937–21.137 0.060 5.65 0.651–49.137 0.11 
Progesterone receptor status Negative (RC) vs Positive 2.508 0.322–19.530 0.380    
Lower uterine segment involvement Absent (RC) vs Present 2.192 0.712–6.744 0.171 0.683 0.134–3.474 0.64 
Adjuvant therapy Absent (RC) vs Present 3.584 0.986–13.031 0.053 3.255 0.651–16.262 0.15
1 HR — hazard ratio; CI — confidential interval; BMI — cody mass index; RC — reference category 





Table 5. Time-dependent ROC curve analysis results and accuracy summaries for Ki-67 
Time interval AUC p-value cut-off Youden J Sensitivity Specificity LR+ LR– 
[3.3–3.9) 0.012 1.000 – – – – – – 
[3.9–6.5) 0.495 0.511 – – – – – – 
[6.5–9.2) 0.480 0.555 – – – – – – 
[9.2–13.4) 0.592 0.341 – – – – – – 
[13.4–20) 0.480 0.541 – – – – – – 
[20–21.3) 0.469 0.582 – – – – – – 
[21.3–22.1) 0.523 0.435 – – – – – – 
[22.1–25.8) 0.465 0.601 – – – – – – 
[25.8–26) 0.452 0.668 – – – – – – 
[26–26.4) 0.507 0.474 – – – – – – 
[26.4–32.6) 0.553 0.323 – – – – – – 
[32.6–34.1) 0.520 0.425 – – – – – – 
[34.1–36.2) 0.554 0.309 – – – – – – 
[36.2–38) 0.575 0.225 – – – – – – 
[38–46.7) 0.581 0.185 – – – – – – 
[46.7–51) 0.615 0.101 – – – – – – 
[51–60.1) 0.649 0.052 – – – – – – 
[60.1–64.2) 0.641 0.057 – – – – – – 
[64.2–74.1) 0.658 0.030 30 0.276 0.534 0.742 2.072 0.628 
[74.1–185.6] 0.659 0.016 20 0.268 0.686 0.583 1.643 0.539 





Table 6. Univariate and multivariate cox regression analysis of the predictors for stage 1B patients recurrence 
Factor  Univariate Analysis Multivariate Analysis 
Grade 3-4 
 HR % 95 CI p HR % 95 CI p 
Age Years 0.955 0.907–1.006 0.08
1 
0.959 0.850–1.082 0.492 
BMI kg/m2 1.090 0.983–1.208 0.10
1 
1.084 0.871–1.350 0.469 
DM Absent (RC) vs Present 1.993 0.533–7.448 0.30
5 
   
Parity Nullipar (RC) vs Multipar 0.429 0.089–2.072 0.29
2 
   
Grade   5.371 1.783–16.185  
0.00
3 
5.508 1.169–25.960 0.0310 
Tumor size cm 1.344 0.999–1.808 0.05
1 
1.013 0.434–2.366 0.977 
Lymphovascular space invasion Absent (RC) vs Present 0.981 0.139–1.930 0.32
7 
   
Lymph node dissection Absent (RC) vs Present 0.518 0.497–2.675 0.74
1 
   
Adenomiyozis Absent (RC) vs Present 0.842 0.174–4.072 0.83
0 
   
Ki-67 % 1.012 0.918–1.045 0.44
7 
   
Estrogen receptor status Negative (RC) vs Positive 1.598 0.191–13.341 0.66
5 
   
Progesterone receptor status Negative (RC) vs Positive 5.261 0.611–45.289 0.13
1 
4.099 0.357–47.125 0.258 
Lower uterine segment involvement Absent (RC) vs Present 0.498 0.103–2.416 0.38
7 
   
Adjuvant therapy Absent (RC) vs Present 1.899 0.233–15.469 0.54
9 
   
 
 
HR — hazard ratio; CI — confidential interval; BMI — body mass index; RC — reference category; *Cox regression model is statistically 
significant (p = 0.001) 
 
 
Figure 1: Time-dependent ROC curves of A) tumor size for 26.4-32.6 time interval, B) tumor 
size for 74.2-100 time interval, C) Ki-67 for 64.2-74.1 time interval, D) Ki-67 for 74.1-185.6 
time interval 
  
Figure 2: Kaplan-Meier curves of recurrence-free survival according to histologic grade in 
FIGO stage 1B endometrioid endometrial cancer. FIGO: International Federation of 
Gynecology and Obstetrics 
 
 


